Prevalence of IL28B Polymorphism in Hepatitis C Patients

Prevalence of IL28B Polymorphism in Hepatitis C Patients in Singapore and Its Effect on the Outcome of Hepatitis C Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03415009

Enrollment

Registered

2018-01-30

Start date

2014-06-30

Completion date

2016-12-31

Last updated

2018-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Keywords

IL28B gene

Brief summary

Response to peginterferon and ribavirin treatment in hepatitis C (HCV) depends on viral and host factors. Single nucleotide polypmorphisms (SNP) near to IL28B gene (especially at rs12979860 and rs8099917) are strongly associated with the response to treatment in HCV genotype 1 infection, less so in HCV genotype 2/3 infection. CC genotype in rs12979860 and TT genotype at rs8099917 are associated with good treatment outcome. Asian populations have high prevalence of CC genotype in other studies, which can explain relatively good response to peginterferon/ ribavirin in genotype 1 infection in Asians compared with Caucasians.

Detailed description

The prevalence of different genotypes of IL28B polymorphism in the local population will be studied. DNA will be extracted from the whole blood sample of hepatitis C patients with genotype 1, 2 and 3 infection. It will be amplified by real-time PCR and subsequently analysed for the genotypes of IL28B SNPs.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with positive HCV IgG (EIA or RIBA test) and positive HCV RNA test (RT-PCR) * HCV genotypes 1, 2 or 3 (determined by Versant™ HCV genotype Assay LiPA 2.0) * with or without HCV treatment (peginterferon/ ribavirin).

Exclusion criteria

-Patients with acute hepatitis C infection.

Design outcomes

Primary

Measure	Time frame
the prevalence of genetic variants for IL28B SNPs (rs 12979860 and rs 8099917) in HCV patients in Singapore.	Baseline

Secondary

Measure	Time frame	Description
The distribution of the different SNP variants in different ethnic groups (Chinese, Malay, Indian and others)	Baseline	—
The association of the genetic variants and the treatment response in patients receiving peg-interferon/ ribavirin therapy.	Baseline	To study the correlation between genetic variants and treatment response

Countries

Singapore

Outcome results